140 related articles for article (PubMed ID: 21206220)
21. Role of 18F-FDG PET/CT in the assessment of therapy response and clinical outcome in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors or immunotherapy.
Tatar G; Alçin G; Şengül Samanci N; Erol Fenercioglu Ö; Beyhan E; Çermik TF
Nucl Med Commun; 2022 Jun; 43(6):701-709. PubMed ID: 35362692
[TBL] [Abstract][Full Text] [Related]
22. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
[TBL] [Abstract][Full Text] [Related]
23. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.
Juweid ME; Wiseman GA; Vose JM; Ritchie JM; Menda Y; Wooldridge JE; Mottaghy FM; Rohren EM; Blumstein NM; Stolpen A; Link BK; Reske SN; Graham MM; Cheson BD
J Clin Oncol; 2005 Jul; 23(21):4652-61. PubMed ID: 15837965
[TBL] [Abstract][Full Text] [Related]
24. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
25. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
26. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
[TBL] [Abstract][Full Text] [Related]
27. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
Dilhuydy MS; Durieux A; Pariente A; de Clermont H; Pasticier G; Monteil J; Ravaud A
Oncology; 2006; 70(5):339-44. PubMed ID: 17164590
[TBL] [Abstract][Full Text] [Related]
28. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
[TBL] [Abstract][Full Text] [Related]
29. Better late than early: FDG-PET imaging in metastatic renal cell carcinoma.
Harrison MR; George DJ
Clin Cancer Res; 2011 Sep; 17(18):5841-3. PubMed ID: 21926167
[TBL] [Abstract][Full Text] [Related]
30. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
31. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer.
Okada M; Murakami T; Kumano S; Kuwabara M; Shimono T; Hosono M; Shiozaki H
Ann Nucl Med; 2009 Jan; 23(1):73-80. PubMed ID: 19205841
[TBL] [Abstract][Full Text] [Related]
32.
Mittlmeier LM; Unterrainer M; Rodler S; Todica A; Albert NL; Burgard C; Cyran CC; Kunz WG; Ricke J; Bartenstein P; Stief CG; Ilhan H; Staehler M
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2031-2037. PubMed ID: 33369689
[TBL] [Abstract][Full Text] [Related]
33. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
34. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
35. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
36. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
[TBL] [Abstract][Full Text] [Related]
37. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH; Min JJ; Jeong YY; Ahn JS; Kim YK; Cho SH; Chung IJ; Bom HS; Kim HJ; Lee JJ
Ann Hematol; 2009 May; 88(5):425-32. PubMed ID: 19002686
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
[TBL] [Abstract][Full Text] [Related]
39. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
[TBL] [Abstract][Full Text] [Related]
40. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
